BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
about
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.
P2860
BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
BEZ235 (PIK3/mTOR inhibitor) O ...... tory Soft Tissue Sarcoma Cells
@en
BEZ235
@nl
type
label
BEZ235 (PIK3/mTOR inhibitor) O ...... tory Soft Tissue Sarcoma Cells
@en
BEZ235
@nl
prefLabel
BEZ235 (PIK3/mTOR inhibitor) O ...... tory Soft Tissue Sarcoma Cells
@en
BEZ235
@nl
P2093
P2860
P1476
BEZ235 (PIK3/mTOR inhibitor) O ...... tory Soft Tissue Sarcoma Cells
@en
P2093
Dong Woo Lee
Hee Kyung Kim
Jeeyun Lee
Jiryeon Jang
Julia Schueler
Mihyeon Kang
Se Hoon Park
Seung Tae Kim
Su Jin Lee
Sun Young Kim
P2860
P304
P356
10.1016/J.TRANON.2016.03.008
P50
P577
2016-05-12T00:00:00Z